Phaseline

Targets › AGER

AGER (Advanced glycation end product-specific receptor): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 3 Phase 2, 2 Phase 1; Infectious disease, Oncology, Respiratory; next expected readout Dec 2026.

Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, histones, phospholipids and glycosaminoglycans. Advanced glycation end products (AGEs) are nonenzymatically glycosylated proteins which accumulate in vascular tissue…. (UniProt, Q15109)

Open in Phaseline: the race on AGER, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cantex PharmaceuticalsAzeliragon
Advanced glycosylation end product-specific receptor antagonist
AGERPhase 2Glioblastoma; COVID-19; Cancer Related Cognitive Decline; Solid TumorDec 2026
Arrowhead PharmaceuticalsARO-RAGE
RAGE antagonist / inhibitor
AGERPhase 2AsthmaDec 2027

Conditions

Glioblastoma (1) COVID-19 (1) Cancer Related Cognitive Decline (1) Solid Tumor (1) Asthma (1)

Modalities

small molecule (2)

Companies

Cantex Pharmaceuticals (1) Arrowhead Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.